Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Flibanserin (Addyi) Drug Interactions

8/19/2015

 
The FDA approved flibanserin for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.  The drug was approved with a boxed warning and REMS (mandated monitoring) program due to the drug’s adverse effects profile.  Patients receiving flibanserin will need to be monitored closely for drugs they are currently receiving and drugs that may be added in the future.  Flibanserin will have a boxed warning regarding use with alcohol, liver disease and drugs that are moderate or strong inhibitors of CYP3A4 enzymes.  Much of the REMS program incudes mandatory education for physicians and pharmacists regarding the interaction between flibanserin and alcohol, but the long list of drugs that may potentiate the adverse effects with flibanserin warrants consideration in the drug’s use.  

Co-administration of flibanserin and CYP3A4 inducers may lead to a higher risk for very low blood pressure or loss of consciousness (syncope).  The CYP3A4 enzymes are the most prevalent CYP enzymes in the liver and involved in the metabolism of a large percentage of drugs.  A 1997 article estimated that CYP3A4 enzymes metabolized half of all drugs.  The macrolides, azole antifungals and protease inhibitors drug classes all have several drugs that inhibit CYP3A4.  Additional information will become available from popular references as more information is released.  Here are some common drugs that are strong inhibitors of CYP3A4 to consider:

  • Antibiotics: clarithromycin, ciprofloxacin, erythromycin and telithromycin
  • Antifungals: itraconazole, fluconazole, ketoconazole, posaconazole, miconazole and voriconazole
  • Protease inhibitors: Amprenavir, fosamprenavir, atazanavir, darunavir, ritonavir, indinavir, lopinavir, nelfinavir, saquinavir, telaprevir
  • Antidepressants: nefazodone 
  • Calcium channel blockers: diltiazem and verapamil.
  • Antiarrhythmics: Amiodarone 
  • Hypernatremia treatment: Conivaptan
  • Antiemetics: Aprepitant
  • Cancer Chemotherapy: Imatinib
  • Antivirals for Hepatitis C: Boceprevir
  • Grapefruit juice: can be a moderate o strong inhibitor depending on concentration

References

FDA press release for flibanserin approval
FDA Drug Interaction Table
Hansten and Horn review of CYP3A4 interactions
Classification of the inhibition strength of some common CYP3A4 inhibitors
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.